Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Healthcare

EBOS Group Limited (ASX:EBO): What Do FY26 Earnings and Distribution Investments Signal?

The EBOS (ASX:EBO) portfolio spans community pharmacy distribution, hospital medicines, medical technology, contract logistics, retail pharmacy brands and animal care. Its healthcare activities serve pharmacies, hospitals and other providers, while its animal-care operations include wholesale distribution and branded pet products. The group operates across …

Aditi Sarkar | 12 November 2026

Neuren Pharmaceuticals (ASX:NEU): How Did DAYBUE Sales Change Its 2026 Outlook?

Neuren (ASX:NEU) receives royalty and milestone income linked to trofinetide, commercialised by partner Acadia Pharmaceuticals under the DAYBUEBrandin the United States and other approved markets. The company’s wholly owned investigational asset NNZ-2591, also called ercanetide, is being studied in several neurodevelopmental conditions. Its commercial …

Aditi Sarkar | 12 November 2026

Mesoblast (ASX:MSB): Ryoncil Revenue and Rexlemestrocel-L Plans in Focus

Mesoblast (ASX:MSB) develops therapies derived from mesenchymal lineage cells. Its approved product Ryoncil, or remestemcel-L-rknd, treats steroid-refractory acute graft-versus-host disease in paediatric patients aged two months and older in the United States. The company also maintains clinical programmes for inflammatory chronic low back pain …

Aditi Sarkar | 12 November 2026

PYC Therapeutics (ASX:PYC): What Progress Has Its RNA Medicine Pipeline Made?

PYC Therapeutics (ASX:PYC) applies peptide-conjugated oligonucleotide technology to investigational medicines designed to address genetic causes of disease. Its development activities include PYC-003 for polycystic kidney disease, PYC-002 for Phelan-McDermid syndrome, PYC-001 for autosomal dominant optic atrophy and VP-001 for retinitis pigmentosa type 11. These …

Aditi Sarkar | 12 November 2026

Regis Healthcare (ASX:REG): What Do Occupancy and FY26 Earnings Reveal?

Regis Healthcare (ASX:REG) operates residential aged care homes and related support services for older Australians. Its activities include permanent residential accommodation, home care, day therapy, respite and retirement living. The company describes care and workforce provision as central operating requirements, alongside management of residential …

Aditi Sarkar | 12 November 2026

Nanosonics (ASX:NAN): FY26 trophon Results and the Next Stage for CORIS

Nanosonics (ASX:NAN) operates internationally, with trophon technology used for high-level disinfection of compatible ultrasound probes. TheBusinessincludes equipment sales, consumables, service and related products. It also develops the CORIS system for endoscope reprocessing, which is at a different commercial stage. The distinction matters: trophon already …

Aditi Sarkar | 12 November 2026

Cogstate (ASX:CGS): How Are Mood-Disorder Trials Changing Its Contract Mix?

Cogstate (ASX:CGS) works with drug developers undertaking central nervous system research, where consistent measurement of cognition and other clinical outcomes is important to trial execution. Its activities include cognitive testing, rater training, data-quality programs and related services. The company also serves healthcare customers using …

Aditi Sarkar | 12 November 2026

Integral Diagnostics Limited (ASX:IDX): What Do FY26 Earnings and Imaging Integration Reveal?

Integral Diagnostics (ASX:IDX) delivers medical imaging through clinics and specialist radiologists. Its services include modalities used to diagnose and monitor medical conditions, with clinic capacity, reporting turnaround times and the availability of clinical staff affecting service delivery. The business also uses teleradiology, under which …

Aditi Sarkar | 12 November 2026

PolyNovo Limited (ASX:PNV): FY26 Wound-Care Sales, Profit and Manufacturing Progress

PolyNovo (ASX:PNV) markets NovoSorb Biodegradable Temporising Matrix, or BTM, and NovoSorb MTX. These products address different wound-management applications and are marketed through an international commercial structure. The United States accounts for a material share of commercial revenue, while other markets contribute through established and …

Aditi Sarkar | 12 November 2026

Australian Clinical Labs Limited (ASX:ACL): What Changed in FY26 Pathology Earnings?

Australian Clinical Labs (ASX:ACL) provides routine and specialised pathology testing, including haematology, microbiology, chemical pathology, genetic testing and other diagnostic services. Its network of approved collection centres receives patient samples that are then processed at accredited laboratories. TheBusinessserves community and hospital settings, with operating …

Aditi Sarkar | 12 November 2026
Support

Hi! How can we help you today?

Loading…